Orchard Therapeutics Plc Stock Fundamentals
Orchard Therapeutics PLC fundamentals help investors to digest information that contributes to Orchard Therapeutics' financial success or failures. It also enables traders to predict the movement of Orchard Stock. The fundamental analysis module provides a way to measure Orchard Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orchard Therapeutics stock.
Orchard |
Orchard Therapeutics PLC Company Return On Equity Analysis
Orchard Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orchard Therapeutics Return On Equity | -0.72 |
Most of Orchard Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orchard Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Orchard Therapeutics PLC has a Return On Equity of -0.7151. This is 97.02% lower than that of the Biotechnology sector and 98.04% lower than that of the Health Care industry. The return on equity for all United States stocks is 130.68% higher than that of the company.
Orchard Therapeutics PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orchard Therapeutics's current stock value. Our valuation model uses many indicators to compare Orchard Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orchard Therapeutics competition to find correlations between indicators driving Orchard Therapeutics's intrinsic value. More Info.Orchard Therapeutics PLC is rated below average in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orchard Therapeutics' earnings, one of the primary drivers of an investment's value.Orchard Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orchard Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orchard Therapeutics could also be used in its relative valuation, which is a method of valuing Orchard Therapeutics by comparing valuation metrics of similar companies.Orchard Therapeutics is currently under evaluation in return on equity category among its peers.
Orchard Fundamentals
| Return On Equity | -0.72 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (3.43) % | |||
| Current Valuation | 302.52 M | |||
| Shares Outstanding | 22.76 M | |||
| Shares Owned By Insiders | 12.20 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 27.2 K | |||
| Price To Earning | (8.06) X | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 17.41 X | |||
| Revenue | 21.84 M | |||
| Gross Profit | (76.52 M) | |||
| EBITDA | (99.34 M) | |||
| Net Income | (72.92 M) | |||
| Cash And Equivalents | 170.89 M | |||
| Cash Per Share | 1.35 X | |||
| Total Debt | 58.09 M | |||
| Debt To Equity | 0.41 % | |||
| Current Ratio | 4.24 X | |||
| Book Value Per Share | 3.53 X | |||
| Cash Flow From Operations | (93.32 M) | |||
| Short Ratio | 0.29 X | |||
| Earnings Per Share | (4.10) X | |||
| Target Price | 16.0 | |||
| Number Of Employees | 166 | |||
| Beta | 0.55 | |||
| Market Capitalization | 380.11 M | |||
| Total Asset | 218.91 M | |||
| Retained Earnings | (900.88 M) | |||
| Working Capital | 107.58 M | |||
| Current Asset | 300.47 M | |||
| Current Liabilities | 46.52 M | |||
| Z Score | -2.64 | |||
| Net Asset | 218.91 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Orchard Stock
If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |